Cargando…

Prognostic Factors for Advanced Pancreatic Cancer Treated with Gemcitabine Plus S-1: Retrospective Analysis and Development of a Prognostic Model

Gemcitabine plus S-1 (GS) is commonly used to treat advanced pancreatic cancer (APC) in Asia. Few clinical experiments have demonstrated the clinical efficacy of GS in routine clinical practice. We aimed to identify the prognostic factors and develop a prognostic model for survival prediction in pat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chang, Ching-Fu, Huang, Pei-Wei, Chen, Jen-Shi, Chen, Yen-Yang, Lu, Chang-Hsien, Chang, Pei-Hung, Hung, Yu-Shin, Chou, Wen-Chi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6356456/ https://www.ncbi.nlm.nih.gov/pubmed/30634387 http://dx.doi.org/10.3390/cancers11010057

Ejemplares similares

Validation and application of a prognostic model for patients with advanced pancreatic cancer receiving palliative chemotherapy
por: Huang, Pei‐Wei, et al.
Publicado: (2019)

Venous Thromboembolism in Asian Patients with Pancreatic Cancer Following Palliative Chemotherapy: Low Incidence but a Negative Prognosticator for Those with Early Onset
por: Chen, Jen-Shi, et al.
Publicado: (2018)

Incidence, Risk Factors, and Outcomes of Arterial Thromboembolism in Patients with Pancreatic Cancer Following Palliative Chemotherapy
por: Hung, Yu-Shin, et al.
Publicado: (2018)

Evolution of the chemotherapeutic landscape and survival outcome in patients with metastatic pancreatic cancer: a four-institute cohort study in Taiwan, 2010–2016
por: Chou, Wen-Chi, et al.
Publicado: (2019)

Effect of S‐1 on survival outcomes in 838 patients with advanced pancreatic cancer: A 7‐year multicenter observational cohort study in Taiwan
por: Lai, Hsiang‐Lan, et al.
Publicado: (2019)

The application of the palliative prognostic index, charlson comorbidity index, and Glasgow prognostic score in predicting the life expectancy of patients with hematologic malignancies under palliative care
por: Chou, Wen-Chi, et al.
Publicado: (2015)

Development and Validation of a Prognostic Score to Predict Survival in Adult Patients With Solid Tumors and Bone Marrow Metastases
por: Chou, Wen-Chi, et al.
Publicado: (2015)

Association of time interval between cancer diagnosis and initiation of palliative chemotherapy with overall survival in patients with unresectable pancreatic cancer
por: Lee, Shu‐Hui, et al.
Publicado: (2019)

Timing of chemotherapy-induced neutropenia: the prognostic factor in advanced pancreatic cancer patients treated with gemcitabine / gemcitabine-based chemotherapy
por: Chen, Yang, et al.
Publicado: (2017)

Glasgow prognostic score after concurrent chemoradiotherapy is a prognostic factor in advanced head and neck cancer
por: Chang, Pei-Hung, et al.
Publicado: (2017)

Validation and Comparison of the 7(th) Edition of the American Joint Committee on Cancer Staging System and Other Prognostic Models to Predict Relapse-Free Survival in Asian Patients with Parotid Cancer
por: Lu, Chang-Hsien, et al.
Publicado: (2016)

Prognostic nomogram for nonresectable pancreatic cancer treated with gemcitabine-based chemotherapy
por: Hamada, T, et al.
Publicado: (2014)

Therapeutic outcomes and prognostic factors in unresectable gallbladder cancer treated with gemcitabine plus cisplatin
por: You, Min su, et al.
Publicado: (2019)

Prognostic significance of sarcopenia as determined by bioelectrical impedance analysis in patients with advanced pancreatic cancer receiving gemcitabine plus nab-paclitaxel: A retrospective study
por: Tozuka, Yuichiro, et al.
Publicado: (2022)

Lung Metastases in Patients with Stage IV Pancreatic Cancer: Prevalence, Risk Factors, and Survival Impact
por: Liu, Keng-Hao, et al.
Publicado: (2019)

Prognostic factors of survival in patients treated with nab-paclitaxel plus gemcitabine regimen for advanced or metastatic pancreatic cancer: A single institutional experience
por: Lo Re, Giovanni, et al.
Publicado: (2015)

Efficacy of Nab-Paclitaxel Plus Gemcitabine and Prognostic Value of Peripheral Neuropathy in Patients with Metastatic Pancreatic Cancer
por: You, Min Su, et al.
Publicado: (2018)

Prognostic and predictive factors for Taiwanese patients with advanced biliary tract cancer undergoing frontline chemotherapy with gemcitabine and cisplatin: a real-world experience
por: Wu, Chiao-En, et al.
Publicado: (2020)

Gemcitabine plus concurrent irreversible electroporation vs gemcitabine alone for locally advanced pancreatic cancer
por: Ma, Yang-Yang, et al.
Publicado: (2020)

Prognostic significance of lung radiation dose in patients with esophageal cancer treated with neoadjuvant chemoradiotherapy
por: Lin, Jhen-Bin, et al.
Publicado: (2019)

A Prognostic Model Based on Circulating Tumour Cells is Useful for Identifying the Poorest Survival Outcome in Patients with Metastatic Colorectal Cancer
por: Chou, Wen-Chi, et al.
Publicado: (2018)

Phase II Trial of Erlotinib Plus Gemcitabine Chemotherapy in Korean Patients with Advanced Pancreatic Cancer and Prognostic Factors for Chemotherapeutic Response
por: Park, Semi, et al.
Publicado: (2013)

Comparison of gemcitabine plus oxaliplatin versus gemcitabine plus nab‐paclitaxel as first‐line chemotherapy for advanced pancreatic adenocarcinoma: A single‐center retrospective analysis
por: Schlick, Konstantin, et al.
Publicado: (2023)

Clinical characteristics and blood/serum bound prognostic biomarkers in advanced pancreatic cancer treated with gemcitabine and nab-paclitaxel
por: Blomstrand, Hakon, et al.
Publicado: (2020)

A Modified Regimen of 21-day Nab-Paclitaxel Plus Gemcitabine in Locally Advanced or Metastatic Pancreatic Cancer: A Retrospective Real-World Study
por: Chang, Chen, et al.
Publicado: (2022)

Clinical Prognostic Factors in Patients With Metastatic Adrenocortical Carcinoma Treated With Second Line Gemcitabine Plus Capecitabine Chemotherapy
por: Grisanti, Salvatore, et al.
Publicado: (2021)

Prognostic nomogram for patients with unresectable pancreatic cancer treated with gemcitabine plus nab–paclitaxel or FOLFIRINOX: A post–hoc analysis of a multicenter retrospective study in Japan (NAPOLEON study)
por: Shibuki, Taro, et al.
Publicado: (2022)

Gemcitabine plus S-1 for metastatic pancreatic cancer
por: Zhu, Hong, et al.
Publicado: (2018)

Rituximab in combination with gemcitabine plus cisplatin in patients with recurrent and metastatic head and neck squamous cell carcinoma: a phase I trial
por: Hsieh, Ching-Yun, et al.
Publicado: (2022)

Efficacy and safety of gemcitabine plus S-1 vs. gemcitabine plus nab-paclitaxel in treatment-naïve advanced pancreatic ductal adenocarcinoma
por: Zhu, Zhou, et al.
Publicado: (2023)

Impaired Chromatin Remodeling Predicts Better Survival to Modified Gemcitabine and S-1 plus Nivolumab in Advanced Biliary Tract Cancer: A Phase II T1219 Study
por: Chiang, Nai-Jung, et al.
Publicado: (2022)

Prognostic Factors for Risk Stratification of Patients with Recurrent or Metastatic Pancreatic Adenocarcinoma Who Were Treated with Gemcitabine-Based Chemotherapy
por: Park, Inkeun, et al.
Publicado: (2016)

Impact of body mass index on long-term survival outcome in Asian populations with solid cancer who underwent curative-intent surgery: A six-year multicenter observational cohort study
por: Hung, Chia-Yen, et al.
Publicado: (2018)

Erlotinib plus gemcitabine versus gemcitabine for pancreatic cancer: real-world analysis of Korean national database
por: Shin, Sangjin, et al.
Publicado: (2016)

Real-world outcomes of adjuvant gemcitabine versus gemcitabine plus capecitabine for resected pancreatic ductal adenocarcinoma
por: Kang, Sora, et al.
Publicado: (2022)

RRM1 Expression as a Prognostic Biomarker for Unresectable or Recurrent Biliary Tract Cancer Treated with Gemcitabine plus Cisplatin
por: Chun, Jung Won, et al.
Publicado: (2021)

Comparison of adjuvant nab-paclitaxel plus gemcitabine, S-1 and gemcitabine chemotherapy for resectable pancreatic cancer: a real-world study
por: Li, Haorui, et al.
Publicado: (2023)

Retrospective study of prognostic factors in pediatric invasive pneumococcal disease
por: Chiu, Nan-Chang, et al.
Publicado: (2017)

TP53 Mutational Analysis Enhances the Prognostic Accuracy of IHC4 and PAM50 Assays
por: Lin, Ching-Hung, et al.
Publicado: (2015)

The Prognostic Value of Circulating Tumor Cells in Asian Neuroendocrine Tumors
por: Hsieh, Jason Chia-Hsun, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_ku237i5srcg4caa6bvrfv4uf5t